Forbion, a Dutch life sciences venture capital firm, hired former Dyne Therapeutics CEO Josh Brumm as a general partner Thursday morning.

Brumm, who previously helmed the estimated $3.5 billion Forbion portfolio company, led Dyne through its initial public offering on the Nasdaq in 2020.

He also aided in the advancement of two rare muscle disease programs into clinical trials, including an experimental treatment for Duchenne muscular dystrophy, which showed promise in data from a small Phase 1/2 trial released in early January.

Brumm stepped down from Dyne in March to pursue opportunities in healthcare investing and was succeeded by John Cox, a member of the board of directors.

Before his five year stint at Dyne, Brumm held leadership roles in other biotech companies such as Kaleido Biosciences, Aravive, Pharmacyclics, Zeltiq Aesthetics and Proteolix. 

“I am delighted to be joining Forbion,” he said in a statement. “Having worked with the firm over a number of years as the CEO of a Forbion portfolio company, I know first-hand the quality of the team and feel privileged to be working more closely with them. I look forward to helping them build great biotech companies, supporting their existing portfolio, and bringing transformative therapies to patients.”

Martien Van Osch, co-founder and MP at Forbion, commended Brumm’s track record as a biotech leader in a company press release and heralded his IPO and fundraising work.

In addition to the leadership announcement, Forbion also unveiled plans to expand its existing footprint throughout the U.S., noting that it will be opening an office in Boston.

Forbion currently has roughly 30% of its portfolio companies based in North America. 

In his role at Forbion, Brumm will be mainly focused on bringing his strategic insights and network to create opportunities for the company throughout North America and Europe. 

“The new office provides our firm with a location in the heart of the Boston biotech hub to support our long-standing activities in the U.S. market.” Van Osch stated. “Opening an office in Boston is a natural next step for Forbion, supporting our existing portfolio in both Europe and North America.” 

These announcements also came just over a week after Forbion raised a new €75 million fund.